Can Oryzon Genomics, S.A. turn iadademstat into a platform therapy for acute myeloid leukemia?
Can Oryzon Genomics turn iadademstat into a scalable AML platform therapy? Explore the EHA 2026 clinical and commercial implications.
Pharma & Biotech
Pharma & Biotech
Can Annamycin bridge cytotoxic therapy and immunotherapy in pancreatic cancer?
Find out how Annamycin could bridge chemotherapy and immunotherapy in pancreatic cancer and what AACR 2026 data signals for future trials.
Pharma & Biotech
Can Orum Therapeutics crack one of AML’s hardest problems with ORM-1153? AACR 2026 data spark fresh attention
Orum Therapeutics unveiled AACR 2026 data for ORM-1153 in AML. Read why the CD123 degrader strategy could matter for efficacy and tolerability.
Pharma & Biotech
How Orum Therapeutics plans to solve GSPT1 toxicity with a DAC approach in AML
Orum Therapeutics presents ORM-1153 DAC preclinical data at AACR 2026, including primate safety findings ahead of a planned AML IND filing. Read the analysis.
Pharma & Biotech
Ficlatuzumab joins Beat AML trial: is AVEO’s c-Met inhibitor ready for broader testing?
AVEO begins new trial of ficlatuzumab in front-line AML with Beat AML. Find out what this signals for older patients and c-Met inhibitor development.
Pharma & Biotech
Is Ossium Health redefining bone marrow transplants with off-the-shelf cryopreservation?
Ossium Health’s cryopreserved bone marrow is showing early clinical success. Find out how this could disrupt allogeneic transplantation logistics.
Pharma & Biotech
Will IFx-2.0 and TBS-2025 push TuHURA into the frontline of resistance-focused oncology?
TuHURA Biosciences, Inc. has announced a comprehensive corporate update that includes progress across three of its major immuno-oncology programs. The update covers the company’s lead asset IFx-2.0, currently in a Phase 3 trial in combination with pembrolizumab for advanced Merkel cell carcinoma; the next-stage development of TBS-2025, a VISTA-blocking monoclonal antibody being advanced for relapsed